Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Suppression of thymosin β10 increases cell migration and metastasis of cholangiocarcinoma

Authors: Sirinapa Sribenja, Kanlayanee Sawanyawisuth, Ratthaphol Kraiklang, Chaisiri Wongkham, Kulthida Vaeteewoottacharn, Sumalee Obchoei, Qizhi Yao, Sopit Wongkham, Changyi Chen

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Thymosin β10 (Tβ10) expression is associated with malignant phenotypes in many cancers. However, the role and mechanisms of Tβ10 in liver fluke-associated cholangiocarcinoma (CCA) are not fully understood. In this study, we investigated the expression of Tβ10 in CCA tumor tissues and cell lines as well as molecular mechanisms of Tβ10 in tumor metastasis of CCA cell lines.

Methods

Tβ10 expression was determined by real time RT-PCR or immunocytochemistry. Tβ10 silence or overexpression in CCA cells was achieved using gene delivery techniques. Cell migration was assessed using modified Boyden chamber and wound healing assay. The effect of silencing Tβ10 on CCA tumor metastasis was determined in nude mice. Phosphorylation of ERK1/2 and the expression of EGR1, Snail and matrix metalloproteinases (MMPs) were studied.

Results

Ten pairs of CCA tissues (primary and metastatic tumors) and 5 CCA cell lines were studied. With real time RT-PCR and immunostaining analysis, Tβ10 was highly expressed in primary tumors of CCA; while it was relatively low in the metastatic tumors. Five CCA cell lines showed differential expression levels of Tβ10. Silence of Tβ10 significantly increased cell migration, invasion and wound healing of CCA cells in vitro; reversely, overexpression of Tβ10 reduced cell migration compared with control cells (P<0.05). In addition, silence of Tβ10 in CCA cells increased liver metastasis in a nude mouse model of CCA implantation into the spleen. Furthermore, silence of Tβ10 activated ERK1/2 and increased the expression of Snail and MMPs in CCA cell lines. Ras-GTPase inhibitor, FPT inhibitor III, effectively blocked Tβ10 silence-associated ERK1/2 activation, Snail expression and cell migration.

Conclusions

Low expression of Tβ10 is associated with metastatic phenotype of CCA in vitro and in vivo, which may be mediated by the activation of Ras, ERK1/2 and upregulation of Snail and MMPs. This study suggests a new molecular pathway of CCA pathogenesis and a novel strategy to treat or prevent CCA metastasis.
Appendix
Available only for authorised users
Literature
1.
Shaib Y, El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004, 24: 115-125. 10.1055/s-2004-828889.CrossRefPubMed
2.
Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M, Pairojkul C, Bhudhisawasdi V, Tesana S, Thinkamrop B, et al: Liver fluke induces cholangiocarcinoma. PLoS Med. 2007, 4: e201-10.1371/journal.pmed.0040201.CrossRefPubMedPubMedCentral
3.
Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC: Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002, 37: 806-813. 10.1016/S0168-8278(02)00297-0.CrossRefPubMed
4.
5.
Vatanasapt V, Uttaravichien T, Mairiang EO, Pairojkul C, Chartbanchachai W, Haswell-Elkins M: Cholangiocarcinoma in north-east Thailand. Lancet. 1990, 335: 116-117.CrossRefPubMed
6.
Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD: Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004, 99: 523-526. 10.1111/j.1572-0241.2004.04067.x.CrossRefPubMed
7.
Anderson CD, Pinson CW, Berlin J, Chari RS: Diagnosis and treatment of cholangiocarcinoma. Oncologist. 2004, 9: 43-57.CrossRefPubMed
8.
Kawarada Y, Yamagiwa K, Das BC: Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg. 2002, 183: 679-685. 10.1016/S0002-9610(02)00853-X.CrossRefPubMed
9.
Sawanyawisuth K, Wongkham C, Araki N, Zhao Q, Riggins GJ, Wongkham S: Serial analysis of gene expression reveals promising therapeutic targets for liver fluke-associated cholangiocarcinoma. Asian Pac J Cancer Prev. 2012, 13: 89-93.PubMed
10.
Goldstein AL: History of the discovery of the thymosins. Ann N Y Acad Sci. 2007, 1112: 1-13. 10.1196/annals.1415.045.CrossRefPubMed
11.
Goldstein AL, Hannappel E, Sosne G, Kleinman HK: Thymosin beta(4): a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012, 12: 37-51. 10.1517/14712598.2012.634793.CrossRefPubMed
12.
13.
Huff T, Muller CS, Otto AM, Netzker R, Hannappel E: Beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001, 33: 205-220. 10.1016/S1357-2725(00)00087-X.CrossRefPubMed
14.
Chen C, Li M, Yang H, Chai H, Fisher W, Yao Q: Roles of thymosins in cancers and other organ systems. World J Surg. 2005, 29: 264-270. 10.1007/s00268-004-7817-2.CrossRefPubMed
15.
Sribenja S, Li M, Wongkham S, Wongkham C, Yao Q, Chen C: Advances in thymosin beta10 research: differential expression, molecular mechanisms, and clinical implications in cancer and other conditions. Cancer Invest. 2009, 27: 1016-1022. 10.3109/07357900902849640.CrossRefPubMed
16.
Sribenja S, Wongkham S, Wongkham C, Yao Q, Chen C: Roles and mechanisms of beta-thymosins in cell migration and cancer metastasis: an update. Cancer Invest. 2012, 31: 103-110.CrossRef
17.
Califano D, Monaco C, Santelli G, Giuliano A, Veronese ML, Berlingieri MT, de Franciscis V, Berger N, Trapasso F, Santoro M, et al: Thymosin beta-10 gene overexpression correlated with the highly malignant neoplastic phenotype of transformed thyroid cells in vivo and in vitro. Cancer Res. 1998, 58: 823-828.PubMed
18.
Takano T, Hasegawa Y, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K, Amino N: Quantitative analysis of thymosin beta-10 messenger RNA in thyroid carcinomas. Jpn J Clin Oncol. 2002, 32: 229-232. 10.1093/jjco/hyf054.CrossRefPubMed
19.
Weterman MA, van Muijen GN, Ruiter DJ, Bloemers HP: Thymosin beta-10 expression in melanoma cell lines and melanocytic lesions: a new progression marker for human cutaneous melanoma. Int J Cancer. 1993, 53: 278-284. 10.1002/ijc.2910530218.CrossRefPubMed
20.
Huang L, Zheng M, Zhou QM, Zhang MY, Jia WH, Yun JP, Wang HY: Identification of a gene-expression signature for predicting lymph node metastasis in patients with early stage cervical carcinoma. Cancer. 2011, 117: 3363-3373. 10.1002/cncr.25870.CrossRefPubMed
21.
Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripa C, Miwa M: Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol. 2005, 11: 3392-3397.CrossRefPubMedPubMedCentral
22.
Obchoei S, Weakley SM, Wongkham S, Wongkham C, Sawanyawisuth K, Yao Q, Chen C: Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma. Mol Cancer. 2011, 10: 102-10.1186/1476-4598-10-102.CrossRefPubMedPubMedCentral
23.
Li M, Zhang Y, Zhai Q, Feurino LW, Fisher WE, Chen C, Yao Q: Thymosin beta-10 is aberrantly expressed in pancreatic cancer and induces JNK activation. Cancer Invest. 2009, 27: 251-256. 10.1080/07357900802254016.CrossRefPubMedPubMedCentral
24.
Lee SH, Son MJ, Oh SH, Rho SB, Park K, Kim YJ, Park MS, Lee JH: Thymosin {beta}(10) inhibits angiogenesis and tumor growth by interfering with Ras function. Cancer Res. 2005, 65: 137-148.PubMed
25.
Gineitis D, Treisman R: Differential usage of signal transduction pathways defines two types of serum response factor target gene. J Biol Chem. 2001, 276: 24531-24539. 10.1074/jbc.M102678200.CrossRefPubMed
26.
Guha M, O’Connell MA, Pawlinski R, Hollis A, McGovern P, Yan SF, Stern D, Mackman N: Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood. 2001, 98: 1429-1439. 10.1182/blood.V98.5.1429.CrossRefPubMed
27.
Shin SY, Lee JH, Min B, Lee YH: The translation inhibitor anisomycin induces Elk-1-mediated transcriptional activation of egr-1 through multiple mitogen-activated protein kinase pathways. Exp Mol Med. 2006, 38: 677-685. 10.1038/emm.2006.80.CrossRefPubMed
28.
Cagnol S, Rivard N: Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. Oncogene. 2013, 32: 564-576. 10.1038/onc.2012.88.CrossRefPubMed
29.
Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25: 9-34. 10.1007/s10555-006-7886-9.CrossRefPubMed
30.
Gu Y, Wang C, Wang Y, Qiu X, Wang E: Expression of thymosin beta10 and its role in non-small cell lung cancer. Hum Pathol. 2009, 40: 117-124. 10.1016/j.humpath.2008.06.023.CrossRefPubMed
31.
Liu CR, Ma CS, Ning JY, You JF, Liao SL, Zheng J: Differential thymosin beta 10 expression levels and actin filament organization in tumor cell lines with different metastatic potential. Chin Med J (Engl). 2004, 117: 213-218.
32.
Santelli G, Califano D, Chiappetta G, Vento MT, Bartoli PC, Zullo F, Trapasso F, Viglietto G, Fusco A: Thymosin beta-10 gene overexpression is a general event in human carcinogenesis. Am J Pathol. 1999, 155: 799-804. 10.1016/S0002-9440(10)65178-4.CrossRefPubMedPubMedCentral
33.
van Groningen JJ, Cornelissen IM, van Muijen GN, Bloemers HP, Swart GW: Simultaneous suppression of progression marker genes in the highly malignant human melanoma cell line BLM after transfection with the adenovirus-5 E1A gene. Biochem Biophys Res Commun. 1996, 225: 808-816. 10.1006/bbrc.1996.1255.CrossRefPubMed
34.
Verghese-Nikolakaki S, Apostolikas N, Livaniou E, Ithakissios DS, Evangelatos GP: Preliminary findings on the expression of thymosin beta-10 in human breast cancer. Br J Cancer. 1996, 74: 1441-1444. 10.1038/bjc.1996.562.CrossRefPubMedPubMedCentral
35.
Chiappetta G, Pentimalli F, Monaco M, Fedele M, Pasquinelli R, Pierantoni GM, Ribecco MT, Santelli G, Califano D, Pezzullo L, Fusco A: Thymosin beta-10 gene expression as a possible tool in diagnosis of thyroid neoplasias. Oncol Rep. 2004, 12: 239-243.PubMed
36.
Feher LZ, Pocsay G, Krenacs L, Zvara A, Bagdi E, Pocsay R, Lukacs G, Gyory F, Gazdag A, Tarko E, Puskas LG: Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas. Pathol Oncol Res. 2012, 18: 449-458. 10.1007/s12253-011-9467-7.CrossRefPubMed
37.
Hardesty WM, Kelley MC, Mi D, Low RL, Caprioli RM: Protein signatures for survival and recurrence in metastatic melanoma. J Proteomics. 2011, 74: 1002-1014. 10.1016/j.jprot.2011.04.013.CrossRefPubMedPubMedCentral
38.
Mu H, Ohashi R, Yang H, Wang X, Li M, Lin P, Yao Q, Chen C: Thymosin beta10 inhibits cell migration and capillary-like tube formation of human coronary artery endothelial cells. Cell Motil Cytoskeleton. 2006, 63: 222-230. 10.1002/cm.20117.CrossRefPubMed
39.
Wang AG, Yoon SY, Oh JH, Jeon YJ, Kim M, Kim JM, Byun SS, Yang JO, Kim JH, Kim DG, et al: Identification of intrahepatic cholangiocarcinoma related genes by comparison with normal liver tissues using expressed sequence tags. Biochem Biophys Res Commun. 2006, 345: 1022-1032. 10.1016/j.bbrc.2006.04.175.CrossRefPubMed
40.
Bravo-Cordero JJ, Hodgson L, Condeelis J: Directed cell invasion and migration during metastasis. Curr Opin Cell Biol. 2012, 24: 277-283. 10.1016/j.ceb.2011.12.004.CrossRefPubMed
41.
Woodhouse EC, Chuaqui RF, Liotta LA: General mechanisms of metastaisis. Cancer Suppl. 1997, 80: 1529-2537. 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F.CrossRef
42.
Kim YC, Kim BG, Lee JH: Thymosin beta(10) expression driven by the human TERT promoter induces ovarian cancer-specific apoptosis through ROS production. PLoS One. 2012, 7: e35399-10.1371/journal.pone.0035399.CrossRefPubMedPubMedCentral
43.
Lee SH, Zhang W, Choi JJ, Cho YS, Oh SH, Kim JW, Hu L, Xu J, Liu J, Lee JH: Overexpression of the thymosin beta-10 gene in human ovarian cancer cells disrupts F-actin stress fiber and leads to apoptosis. Oncogene. 2001, 20: 6700-6706. 10.1038/sj.onc.1204683.CrossRefPubMed
44.
Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, McPherson JR, Allen GE, Ng CC, Wong BH, et al: Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012, 44: 690-693. 10.1038/ng.2273.CrossRefPubMed
45.
Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003, 3: 330-338. 10.1038/nrc1074.CrossRefPubMed
46.
Huang C, Jacobson K, Schaller MD: MAP kinases and cell migration. J Cell Sci. 2004, 117: 4619-4628. 10.1242/jcs.01481.CrossRefPubMed
47.
Reddy KB, Nabha SM, Atanaskova N: Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 2003, 22: 395-403. 10.1023/A:1023781114568.CrossRefPubMed
48.
Hunger-Glaser I, Salazar EP, Sinnett-Smith J, Rozengurt E: Bombesin, lysophosphatidic acid, and epidermal growth factor rapidly stimulate focal adhesion kinase phosphorylation at Ser-910: requirement for ERK activation. J Biol Chem. 2003, 278: 22631-22643. 10.1074/jbc.M210876200.CrossRefPubMed
49.
Cheng JC, Chang HM, Leung PC: Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells. Oncogene. 2013, 32: 1041-1049. 10.1038/onc.2012.127.CrossRefPubMed
50.
Grotegut S, von Schweinitz D, Christofori G, Lehembre F: Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J. 2006, 25: 3534-3545. 10.1038/sj.emboj.7601213.CrossRefPubMedPubMedCentral
51.
Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mukai M, Okada Y: Expression of Snail and Slug in renal cell carcinoma: E-cadherin repressor Snail is associated with cancer invasion and prognosis. Lab Invest. 2011, 91: 1443-1458. 10.1038/labinvest.2011.111.CrossRefPubMed
52.
Merikallio H, Turpeenniemi-Hujanen T, Pääkkö P, Mäkitaro R, Riitta K, Salo S, Salo T, Harju T, Soini Y: Snail promotes an invasive phenotype in lung carcinoma. Respir Res. 2012, 13: 104-10.1186/1465-9921-13-104.CrossRefPubMedPubMedCentral
53.
Jin H, Yu Y, Zhang T, Zhou X, Zhou J, Jia L, Wu Y, Zhou BP, Feng Y: Snail is critical for tumor growth and metastasis of ovarian carcinoma. Int J Cancer. 2010, 126: 2102-2111.PubMed
54.
Shin NR, Jeong EH, Choi CI, Moon HJ, Kwon CH, Chu IS, Kim GH, Jeon TY, Kim DH, Lee JH, Park Do Y: Overexpression of Snail is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. BMC Cancer. 2012, 12: 521-10.1186/1471-2407-12-521.CrossRefPubMedPubMedCentral
55.
de Herreros AG, Peiro S, Nassour M, Savagner P: Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J Mammary Gland Biol Neoplasia. 2010, 15: 135-147. 10.1007/s10911-010-9179-8.CrossRefPubMedPubMedCentral
56.
Peiro S, Escriva M, Puig I, Barbera MJ, Dave N, Herranz N, Larriba MJ, Takkunen M, Franci C, Munoz A, et al: Snail1 transcriptional repressor binds to its own promoter and controls its expression. Nucleic Acids Res. 2006, 34: 2077-2084. 10.1093/nar/gkl141.CrossRefPubMedPubMedCentral
Metadata
Title
Suppression of thymosin β10 increases cell migration and metastasis of cholangiocarcinoma
Authors
Sirinapa Sribenja
Kanlayanee Sawanyawisuth
Ratthaphol Kraiklang
Chaisiri Wongkham
Kulthida Vaeteewoottacharn
Sumalee Obchoei
Qizhi Yao
Sopit Wongkham
Changyi Chen
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-430

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites

Research article

Time-dependent endpoints as predictors of overall survival in multiple myeloma

Research article

Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9

Research article

Molecular fingerprinting reflects different histotypes and brain region in low grade gliomas

Research article

Design and application of a novel PNA probe for the detection at single cell level of JAK2V617Fmutation in Myeloproliferative Neoplasms

Research article

Alcohol dehydrogenase, iron containing, 1promoter hypermethylation associated with colorectal cancer differentiation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits